Patent US2371983A successfully refreshed from Google Patents.
Patent US4456618A successfully refreshed from Google Patents.
US4456618A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Naphthenic and heterocyclic retinoic acid analogues
Assignee: SRI International Inc
•
Filing: 1982-10-15
•
Granted: 1984-06-26
•
Expires: 2002-10-15
Abstract
Abstract Naphthenic and heterocyclic retinoic acid analogues such as (E)-6-[2-(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl]-2-naphthaldehyde, methyl 6-[2-(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl]-2-naphthoate, 6-[2-(2,6,6-trimethyl-1-cyclohexen-1-yl)ethenyl]-2-naphthoic acid, (E)-1-(5-carbethoxy-2-furanyl)-2-methyl-4-(2,6,6-trimethyl-1-cyclohexe n-1-yl)-1,3-butadiene, (E)-1-(5-carboxy-2-furanyl)-2-methyl-4-(2,6,6-trimethyl-1-cyclohexen-1 -yl)-1,3-butadiene, (E)-1-(5-carbethoxythien-2-yl)-2-methyl-4-(2,6,6-trimethyl-1-cyclohexe n-1-yl)-1,3-butadiene, and (E)-1-(5-carboxythien-2-yl)-2-methyl-4-(2,6,6-trimethyl-1-cyclohexen-1 -yl)-1,3-butadiene. These retinoids are useful as chemopreventive agents for inhibiting tumor promotion in epithelial cells and for treating nonmalignant skin disorders.
Inventors
- 👤 Marcia I. Dawson
- 👤 Rebecca L. S. Chan
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 04:37
CPC Classifications
C; C07; C07D; C07D333/00; C07D333/02; C07D333/04; C07D333/26; C07D333/38; A; A61; A61P; A61P35/00; C07C; C07C45/00; C07C45/61; C07C45/67; C07C45/68; C07C47/00; C07C47/52; C07C47/548; C07C47/55; C07C47/575; C07C63/00; C07C63/66; C07C63/68; C07C63/74; C07D307/00; C07D307/02; C07D307/34; C07D307/56; C07D307/68
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
57 words
A compound of the formula: ##STR7## where R 4 and R 5 are independently hydrogen, fluorine, methyl, or methoxy, and R 6 is ##STR8## or --CH(OR 8 ) 2 where R 2 is hydrogen, alkyl, or aryl, R 3 is alkyl or aryl, R 7 is hydrogen, alkyl or aryl, and R 8 is alkyl or aryl.
Claim 2
Dependent Claim
57 words
A compound of the formula: ##STR7## where R 4 and R 5 are independently hydrogen, fluorine, methyl, or methoxy, and R 6 is ##STR8## or --CH(OR 8 ) 2 where R 2 is hydrogen, alkyl, or aryl, R 3 is alkyl or aryl, R 7 is hydrogen, alkyl or aryl, and R 8 is alkyl or aryl.
Claim 3
Dependent Claim
79 words
The compound of claim 1 wherein the alkyl groups represented by R 2 and R 3 each contain 1 to about 8 carbon atoms, the aryl groups represented by R 2 and R 3 each contains 6 to about 15 carbon atoms, the alkyl groups represented by R 7 and R 8 each contains 1 to about 8 carbon atoms, and the aryll groups, represented by R 7 and R 8 each contains 6 to about 15 carbon atoms.
Claim 4
Dependent Claim
76 words
The compound of claim 1 wherein the alkyl groups represented by R 2 and R 3 each contain 1 to 4 carbon atoms, the aryl groups represented by R 2 and R 3 are phenyl, 4-hydroxyphenyl, or 4-methoxyphenyl, the alkyl groups represented by R 7 and R 8 each contain 1 to 4 carbon atoms, and the aryl groups represented by R 7 and R 8 are mononuclear and each contains 6 to 10 carbon atoms.
Claim 5
Dependent Claim
18 words
The compound of claim 1 wherein R 4 and R 5 are hydrogen and R 6 is ##STR9##
Claim 6
Dependent Claim
20 words
A pharmaceutical composition comprising a pharmaceutically effective amount of the compound of claim 1 combined with a pharmaceutically acceptable carrier.
Claim 7
Dependent Claim
20 words
A pharmaceutical composition comprising a pharmaceutically effective amount of the compound of claim 2 combined with a pharmaceutically acceptable carrier.
Claim 8
Dependent Claim
20 words
A pharmaceutical composition comprising a pharmaceutically effective amount of the compound of claim 3 combined with a pharmaceutically acceptable carrier.
Claim 9
Dependent Claim
20 words
A pharmaceutical composition comprising a pharmaceutically effective amount of the compound of claim 4 combined with a pharmaceutically acceptable carrier.
Claim 10
Dependent Claim
29 words
A method of inhibiting tumor promotion in epithelial cells of a living animal comprising administering a tumor promotion inhibiting amount of the compound of claim 1 to the animal.
Claim 11
Dependent Claim
29 words
A method of inhibiting tumor promotion in epithelial cells of a living animal comprising administering a tumor promotion inhibiting amount of the compound of claim 2 to the animal.
Claim 12
Dependent Claim
29 words
A method of inhibiting tumor promotion in epithelial cells of a living animal comprising administering a tumor promotion inhibiting amount of the compound of claim 3 to the animal.
Claim 13
Dependent Claim
29 words
A method of inhibiting tumor promotion in epithelial cells of a living animal comprising administering a tumor promotion inhibiting amount of the compound of claim 4 to the animal.
Claim 14
Dependent Claim
11 words
The method of claim 9 wherein the animal is a human.
Claim 15
Dependent Claim
27 words
A method of treating a living animal for a nonmalignant skin disorder comprising administering a therapeutically effective amount of the compound of claim 1 to the animal.
Claim 16
Dependent Claim
27 words
A method of treating a living animal for a nonmalignant skin disorder comprising administering a therapeutically effective amount of the compound of claim 2 to the animal.
Claim 17
Dependent Claim
27 words
A method of treating a living animal for a nonmalignant skin disorder comprising administering a therapeutically effective amount of the compound of claim 3 to the animal.
Claim 18
Dependent Claim
27 words
A method of treating a living animal for a nonmalignant skin disorder comprising administering a therapeutically effective amount of the compound of claim 4 to the animal.
Claim 19
Dependent Claim
17 words
The method of claim 14 wherein the compound is administered topically to the affected area of skin.
Claim 20
Dependent Claim
14 words
The method of claim 14 wherein the compound is administered orally to the animal.
Claim 21
Dependent Claim
11 words
The method of claim 14 wherein the animal is a human.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-06-26 | 1987-12-26 | 1988-06-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-06-26 | 1991-12-26 | 1992-06-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-06-26 | 1995-12-26 | 1996-06-26 | $7700.00 | Window Closed / Lapsed |